Ishikawa H, Matsuda Y, Kaneko S, Yazaki T, Umeda T, Fujimoto Y, Akihama S
Department of Urology, Ichikawa General Hospital, Tokyo Dental College, Chiba, Japan.
Nihon Jinzo Gakkai Shi. 1993 Nov;35(11):1277-82.
Two forms of acidic arginine amidases were separated from human kidney extract using the techniques of basic ion exchange adsorption and elution as well as lima bean trypsin inhibitor (LBTI) and aprotinin affinity adsorptions and elutions. The enzymes were tentatively named acidic human renal arginine amidase-L (AHRAA-L, with affinity to an LBTI column) and -A (AHRAA-A, with affinity to an aprotinin column). Both enzymes showed a similar molecular mass of approximately 3.0 x 10(4) daltons, differing from that of human renal kallikrein (HRK, molecular mass of 4.8 x 10(4) daltons). The specific activity of AHRAA-L and -A were 106 and 680 nmol/min/A280 of Val-Leu-Arg-pNA amidolysis, respectively, and they were strongly inhibited by LBTI and human urinary trypsin inhibitor (UTI), while ethylenglycol-bis(beta-amino ethylether)-N,N,N',N'-tetraacetic acid (EGTA) showed a weak or no effect on both enzymes.
利用碱性离子交换吸附与洗脱技术以及利马豆胰蛋白酶抑制剂(LBTI)和抑肽酶亲和吸附与洗脱技术,从人肾提取物中分离出两种酸性精氨酸酰胺酶。这两种酶被暂定为酸性人肾精氨酸酰胺酶-L(AHRAA-L,对LBTI柱有亲和力)和-A(AHRAA-A,对抑肽酶柱有亲和力)。两种酶的分子量均约为3.0×10⁴道尔顿,与人类肾激肽释放酶(HRK,分子量为4.8×10⁴道尔顿)不同。AHRAA-L和-A的比活性分别为106和680 nmol/min/A280(对Val-Leu-Arg-pNA进行酰胺水解),它们受到LBTI和人尿胰蛋白酶抑制剂(UTI)的强烈抑制,而乙二醇双(β-氨基乙醚)-N,N,N',N'-四乙酸(EGTA)对这两种酶的影响较弱或无影响。